check_circleStudy Completed
Erectile Dysfunction
Bayer Identifier:
100519
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study to investigate the efficacy and safety of vardenafil flexible dose versus placebo in males with erectile dysfunction
Trial purpose
Study to investigate the efficacy and safety of vardenafil flexible dose versus placebo in males with erectile dysfunction, and their female partners' sexual quality of life.
Key Participants Requirements
Sex
MaleAge
18 YearsTrial summary
Enrollment Goal
229Trial Dates
October 2003 - August 2004Phase
Phase 3Could I Receive a placebo
YesProducts
Levitra (Vardenafil, BAY38-9456)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Arizona Research Center, Inc. | Phoenix, 85023, United States |
Completed | The Male Clinic | Beverly Hills, 90212, United States |
Completed | St. Paul's Hospital - Saskatoon | Saskatoon, S7M 0Z9, Canada |
Completed | California Professional Research | Newport Beach, 92660, United States |
Completed | Prostate Cancer Institute | Calgary, T2V 4R6, Canada |
Completed | San Diego Uro-Research | San Diego, 92101, United States |
Completed | San Bernardino Urological Associates | San Bernardino, 92404, United States |
Completed | Probity Medical Research/Urology Associates | Kitchener, N2M 5N4, Canada |
Completed | Office of Dr. G.K.Jansz, MD | Burlington, L7N 3V2, Canada |
Completed | The Lipid Center | Statesville, 28677, United States |
Completed | Male/Female Health & Research Centre | Barrie, L4M 4S5, Canada |
Completed | Scripps Clinic | San Diego, 92128, United States |
Completed | Clinical Research Consultants, Inc. | Trumbull, 06611, United States |
Completed | Georgia Urology, PA | Riverdale, 30274, United States |
Completed | Metrolina Medical Research Associates | Charlotte, 28209, United States |
Completed | St.Joseph's Health Care-London | London, N6A 4V2, Canada |
Completed | Robert Wood Johnson Medical School | New Brunswick, 08901, United States |
Completed | The Male Health Centres | Oakville, L6H 3P1, Canada |
Completed | Dr.Peter J.Pommerville, Inc. | Victoria, V8T 5G1, Canada |
Completed | Radiant Research-Irvine | Irvine, 92618-3603, United States |
Completed | New Havover Medical Research Associates | Wilmington, 28412, United States |
Completed | University Urology Associates | New York, 10016, United States |
Completed | Lawrenceville Urology | Lawrenceville, 08648, United States |
Completed | Greenbelt Medical Associates | Greenbelt, 20770, United States |
Completed | Jacksonville Impotence Treatment Center | Jacksonville, 32257, United States |
Completed | Johns Hopkins at Greenspring Station | Lutherville, 21093, United States |
Primary Outcome
- The primary measures of efficacy in this study will be improved success of erection maintenance in men with ED and improvement in female partner's sexual quality of life.date_rangeTime Frame:Weeks 0 -12enhanced_encryptionnoSafety Issue:
Secondary Outcome
- SEP3 at weeks 4 and 12 of treatment compared to placebo.date_rangeTime Frame:Weeks 4 and 12enhanced_encryptionnoSafety Issue:
- Additional Patient Diary questions at 4 weeks, 8 weeks, 12 weeks, LOCF, and over entire treatment period compared to placebo. Per-subject success rates will be calculated as the number of successes divided by the number of sexual attempts with a respdate_rangeTime Frame:Weeks 4, 8 and 12enhanced_encryptionnoSafety Issue:
- Global assessment question (GAQ) at weeks 4 and 12 of treatment compared to placebodate_rangeTime Frame:Weeks 4 and 12enhanced_encryptionnoSafety Issue:
- Global confidence question (GCQ) at 12 weeks of treatment compared to placebo.date_rangeTime Frame:Week 12enhanced_encryptionnoSafety Issue:
- The score for the IIEF questionnaire EF domain (IIEF-EF) at weeks 4, 12, and LOCF of treatment compared to placebodate_rangeTime Frame:Weeks 4 and 12enhanced_encryptionnoSafety Issue:
- Scores from the Treatment Satisfaction Scale (TSS) -- Subject Active Medication module at week 12 and LOCF of treatment compared to placebo. The TSS is a self-report measure of subject and partner's satisfaction with various aspects of erectile functiondate_rangeTime Frame:Week 12enhanced_encryptionnoSafety Issue:
- Scores from the mSLQQ-QOL at week 12 and LOCF of treatment compared to placebodate_rangeTime Frame:Week 12enhanced_encryptionnoSafety Issue:
- Percentage of subjects achieving back to normal rates of erectile functioning (IIEF-EF > 25) at week 12 of treatment compared to placebo.date_rangeTime Frame:Week 12enhanced_encryptionnoSafety Issue:
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
RandomizedBlinding
Double BlindAssignment
Parallel AssignmentTrial Arms
2